Omburtamab (CD276/B7-H3/B7RP-2) - Research Grade Biosimilar
Product Specifications
Background
Omburtamab is monoclonal antibody targeting B7-H3 antigen expressed in a variety of human solid tumors. Omburtamab (alias: 8H9, formerly known as Burtomab) is a monoclonal antibody linked to radioisotope and capable of binding to the B7-H3 antigen on the surface of neuroblastoma cells. Direct injection into cerebrospinal fluid, bypassing the blood-brain barrier, accurately targeting neuroblastoma in the central nervous system, to avoid damage to other tissues (such as learning disabilities and developmental delays often caused by conventional radiotherapy outside the brain) .
Immunogen
Mus musculus / CD276/B7-H3/B7RP-2 [Homo sapiens]
Clonality
Recombinant Monoclonal
Conjugation
Unconjugated
Type
Primary Antibodies, Biosimilars
Source
CHO cells
Field of Research
Cancer, Immunology
Purification
>95%
Concentration
Batch dependent
Buffer
PBS buffer pH7.5
Modification
None
Shipping Conditions
Blue Ice
Storage Conditions
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.
Product Datasheet
https://www.prosci-inc.com/?datasheet_sku=10-915
Fragment
IgG1-kappa
NCBI Organism
Homo sapiens
Other Product Names
8H9, Mab 8H9
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items